PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma

BACKGROUND: The expression of programmed death-ligand 1 (PD-L1) is associated with the response of patients to PD-1/PD-L1 blockade immunotherapy. It has been demonstrated that histone deacetylase (HDAC) inhibitors may alter the expression of PD-L1/PD-L2 and enhance the antitumor immune responses. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhao, Zhang, Lei, Liu, Jianwei, Yang, Lixue, Xue, Hui, Bai, Shilei, Wang, Kui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799021/
https://www.ncbi.nlm.nih.gov/pubmed/35116547
http://dx.doi.org/10.21037/tcr-20-3415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799021/
https://www.ncbi.nlm.nih.gov/pubmed/35116547
http://dx.doi.org/10.21037/tcr-20-3415

Ejemplares similares